Suchergebnisse - "Subbiah, Vivek"

PubPharm (22)

1

Pralsetinib in Patients with Advanced/Metastatic Rearranged During Transfection (RET)-Altered Thyroid Cancer : Updated Efficacy and Safety Data from the ARROW Study

enthalten in: Thyroid : official journal of the American Thyroid Association | 2024

von Subbiah, V. | Hu, M. | Mansfield, A. | +21

ErratumIn: Thyroid. 2024 Apr 16;:. - PMID 38625021

2

Exceptional Responses to Selpercatinib in RET Fusion-Driven Metastatic Pancreatic Cancer

enthalten in: JCO precision oncology | 2023

von Bhamidipati, D. | Yedururi, S. | Huse, J. | +3

3

Selpercatinib in Patients With RET Fusion-Positive Non-Small-Cell Lung Cancer : Updated Safety and Efficacy From the Registrational LIBRETTO-001 Phase I/II Trial

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2023

von Drilon, A. | Subbiah, V. | Gautschi, O. | +15

CommentIn: J Clin Oncol. 2023 Jan 10;41(2):410-412. - PMID 36122320

4

Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001) : a phase 1/2, open-label, basket trial

enthalten in: The Lancet. Oncology | 2022

von Subbiah, V. | Wolf, J. | Konda, B. | +12

CommentIn: Lancet Oncol. 2022 Oct;23(10):1235-1237. - PMID 36108663

5

Pan-cancer efficacy of pralsetinib in patients with RET fusion-positive solid tumors from the phase 1/2 ARROW trial

enthalten in: Nature medicine | 2022

von Subbiah, V. | Cassier, P. | Siena, S. | +16

CommentIn: Nat Rev Clin Oncol. 2022 Oct;19(10):615. - PMID 35999290

6

Addressing challenges with real-world synthetic control arms to demonstrate the comparative effectiveness of Pralsetinib in non-small cell lung cancer

enthalten in: Nature communications | 2022

von Popat, S. | Liu, S. | Scheuer, N. | +5

7

Patient-Reported Outcomes with Selpercatinib Treatment Among Patients with RET-Mutant Medullary Thyroid Cancer in the Phase I/II LIBRETTO-001 Trial

enthalten in: The oncologist | 2022

von Wirth, L. | Robinson, B. | Boni, V. | +8

ErratumIn: Oncologist. 2022 Dec 9;27(12):e982. - PMID 36269631

8

Patient-Reported Outcomes with Selpercatinib Among Patients with RET Fusion-Positive Non-Small Cell Lung Cancer in the Phase I/II LIBRETTO-001 Trial

enthalten in: The oncologist | 2022

von Minchom, A. | Tan, A. | Massarelli, E. | +9

9

Intracranial Efficacy of Selpercatinib in RET Fusion-Positive Non-Small Cell Lung Cancers on the LIBRETTO-001 Trial

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2021

von Subbiah, V. | Gainor, J. | Oxnard, G. | +18

10

Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW) : a multi-cohort, open-label, registrational, phase 1/2 study

enthalten in: The lancet. Diabetes & endocrinology | 2021

von Subbiah, V. | Hu, M. | Wirth, L. | +22

CommentIn: Lancet Diabetes Endocrinol. 2021 Aug;9(8):473-474. - PMID 34126047